CG Oncology Stock Signals Bullish Momentum Ahead

Group 1 - CG Oncology has entered Phase 2 of its 18-phase Adhishthana cycle, transitioning into the Buddhi move period, which is characterized by a higher likelihood of breakouts [1][7] - The stock has rallied approximately 24% since entering the Buddhi period, indicating a shift in momentum [4] - The Buddhi period is expected to last until April 2026, suggesting that bullish momentum could be sustained for an extended period [7] Group 2 - The Adhishthana framework, which combines quantitative signals with behavioral market patterns, has been effective in tracking CG Oncology's stock movements [2] - Large funds have taken notice of CG Oncology, with many holding overweight positions, reflecting a bullish outlook based on the stock's current setup [8] - The stock's previous phase, the Sankhya period, was marked by consolidation, setting the stage for the current bullish potential [5][4]